Try our Advanced Search for more refined results
Life Sciences - August, 2018
314 articles
- Stryker Must Face Suit Over Rep's Alleged Assault Of Nurse
- Pharma Cases To Watch In 2018's Home Stretch
- DOJ, MassBio Back Helsinn In High Court On-Sale Bar Fight
- After High Court Loss, Cos. Say Price Fix Hit Still Wrong
- Ex-Glaxo Scientist Cops To IP Theft For Chinese Pharma Co.
- OvaScience Director Compensation Suit Settled In Del.
- Dealmakers Expect 'Crowded' IPO Calendar After Labor Day
- New Pass-Through Deduction Will Pass Over Many Lawyers
- Health Hires: Quinn Emanuel, Manatt, Strategic, Perkins Coie
- Sexual Enhancement Cos. Barred From Selling Illicit Drugs
- Carlton Fields Nabs Entertainment Litigator For LA Office
- Mallinckrodt Investors Defend False Statements Suit
- How Reckless Judicial Impeachments Threaten Rule Of Law
- Judging A Book: Fogel Reviews 'Good Judgment'
- Taxation With Representation: Sidley, Skadden, Norton
- Adocia Arbitration Claim Against Eli Lilly Climbs To $1.8B
- Medtronic Can't Nix Shareholder Suit Over Merger In Ireland
- DOJ Says It Can Prove Novartis Dinners Were Kickbacks
- Bayer, Janssen Win Another Xarelto Injury Trial In Philly
- Purdue Ends OxyContin Patent Suit With $62M Payout
- Calif. Gets PhRMA's Challenge To Drug Pricing Law Axed
- Enviro Sues Chemours, Alleging NC Water Contamination
- 10 Ways To Prevent E-Discovery Woes
- 3D-Printed Pharmaceuticals? Don't Try This At Home
- The Challenges Of Valuing Litigation-Driven Equities
- Skadden, Simpson Thacher Guide $1.4B Stryker-K2M Deal
- Travel Act Gets Mileage In Health Care Cases
- J&J Hip Implant Plaintiffs Get $245M Judgment After Trial
- Fed. Circ. Impeding Biopharma Innovation, Justices Told
- Allergan, Shire Spar Over Pfizer-J&J Antitrust Ruling
- 4 Health Care Cos. Escape Mass. FCA Suit Over Blood Tests
- 11th Circ. Says Mesh Sling Suit's Injury Notice Beat Time Limit
- Wilson Sonsini Nabs Veteran Hogan Lovells Corporate Atty
- Why Courts Should Apply Escobar In Criminal Cases
- Baker Donelson Nabs IP Atty From Fox Rothschild
- Atty's Restitution Reduced By $12.2M In Stock Scheme
- FDA Warning Wire: Estrogen Drug Promo, Zimmer Quagmire
- Sessions Aide Confirmed To Lead DOJ Civil Division
- 3rd Circ. Revives Heart Monitor Co.'s BCBS Antitrust Suit
- Pfizer Attacks 'False' Biosimilar Info, Urges FDA Action
- Galderma Wins On 5 Patents In Generic Oracea Suit
- Shipping Co. Can't Nix Suit Over Kickback Payments
- McKesson Workers' Narrowed OT Class Gets Conditional Cert.
- CVS Ducks Sentry Data's Antitrust Claim, For Now
- Outset Medical Will Bolster Dialysis Biz With $132M Fund
- Teva Can't Move IP Suits Over Opioid Treatment Drug To Del.
- On-Sale Bar Doesn't Cover Secret Prior Art, Justices Told
- Invisalign Maker Cornered Mouth Scanner Market, Rival Says
- 4 Key Components To New Firm Partnership Agreements
- Par Wants Bulk Vasopressin Compounding Nixed; FDA Agrees
- Hospira Can't Void Amgen's $70M Biosimilar Patent Win
- Deficient Drug Trial Caused Stock Drop, Ampio Investor Says
- Ken Starr Joins Lanier Firm, Returning To Private Practice
- Alvogen Wins Generic Zohydro Case Over Pernix Patents
- Docs' Attys Win $5.7M From $13.5M Botox Pricing Deal
- 1st Circ. Says Challenge To Rx Eyedropper Size Preempted
- Harbour BioMed Lands $85M In Series B Funding
- Gleevec Buyers Ask For Time To Mull 1st Circ. Rehearing Bid
- Amgen Shows New Patents Can Affect Prior BPCIA Litigation
- Goodwin Procter Adds Ex-DLA Piper Life Sciences Pro
- Open The Federal Courthouses
- Woman's J&J Talc Bottle Contained Asbestos, Jury Hears
- Walmart Says Opioid FCA Suit Doesn't Show Medicare Fraud
- Full Fed. Circ. Won't Rethink Upholding UCB's Vimpat Patent
- Ancestry Gets 23andMe Patent Killed, But TM Claims Survive
- Ex-Insys Execs Press Gov't For RICO Indictment Details
- 7th Circ. Focuses On Impossibility Preemption In Dolin V. GSK
- Warner, Lowe's Can't Dodge Benefits Suit, HIV Patients Say
- China Biologic Rejects $3.9B Takeover Bid Led By Ex-CEO
- Incorporating Docs By Reference: New 9th Circ. Law Is Flawed
- FTC Scores Separate Trial In AndroGel Antitrust Row
- Eli Lilly To Face Remaining Claims In Father's Birth Defect Suit
- Investors Need New Leader For Biotech IPO Suit, Judge Says
- Calif. High Court Will Hear Niaspan Pay-For-Delay Appeal
- VC-Backed Bay Area Biotech Files Plans For $80M IPO
- Ex-Shkreli Atty Taps Williams Heavy Hitter For Appeal
- No Clear Winner In $4.3B Akorn Deal Row: Vice Chancellor
- Monsanto Faces 8,000 Glyphosate Suits, Bayer CEO Says
- DePuy Hit With $8.2M Verdict In Implant Patent Fight
- DOJ Urges Toss Of FCA Suit Targeting Opioid Sellers
- Warning Label Suit Over J&J Talc To Stay In Fed. Court
- On-Sale Bar Ruling 'Profoundly Erroneous,' High Court Told
- Don't Allow Patents On Old Ideas, Nonprofits Urge Justices
- Payors Share Some Responsibility For The Opioid Epidemic
- Foley Gardere Snags Baker McKenzie Biotech IP Specialist
- Brexit: Bracing For A No-Deal Scenario
- Trump's Latest China Tariffs Take Effect As Beijing Retaliates
- Bids To Bounce $1B Herbalife RICO Class Action Fall Short
- Morgan Lewis Continues IP Expansion, Adds 9-Partner Team
- Orexigen Says McKesson Can't Nab $7M In Debt Setoff Fight
- CBS Opioid Segments Didn't Defame Pharmacist, Judge Rules
- Pfizer Chips Away At State Claims In Lipitor Antitrust MDL
- Opioid Cos. Slammed With More Suits Over High Health Costs
- PTAB Wrongly Axed Part Of Invisalign Patent, Fed. Circ. Says
- NJ County Aims To Kick McKesson Opioid Suit To State Court
- Reed Smith Atty's Widow Loses $3M GSK Verdict On Appeal
- GSK Can Keep Docs Private In Lamictal Antitrust Suit
- Fed. Circ. Clarifies Enablement Requirement In LED Case
- J&J, Supplier Defend Talc In Latest Trial On Asbestos Link
- 9th Circ. Opinion Could Spark More Securities Settlements
- Contact Lens Makers Look To Dispose Of Pricing Plot Suit
- Attys Relaunch Bid For 'Opioid Babies' Track In MDL
- Novartis Beats Gleevec Monopolization Suit At 1st Circ.
- Orlando Health Hit With $100M Defamation Suit By Fired MD
- Sherwin-Williams Ducks Class Action Over NJ Pollution
- Galena Investors' Stock-Drop Suit Gets Axed, For Now
- FDA Warning Wire: Drug Spec Checks Get Wrecked
- Deals Rumor Mill: GSK, Amaysim, Cepsa
- Omnicare's $1.3M Deal In Credit Reporting Suit OK'd
- Feds Ordered To Hand Over Insys Docs From 10 Agencies
- FTC Pushes For Separate Trial In AndroGel Antitrust Suit
- NJ Justices Centralize Taxotere Hair-Loss Suits
- Internal Docs Led To Couple's $117M Win In J&J Talc Case
- FDA Focus: What Mayer Brown's Practice Chair Is Watching
- In SDNY, Indicting Politicians Is The New Black
- 'High Availability' — A Key Term In Law Firm IT Strategy
- Woman Used Asbestos-Laden J&J Talc, Jury Told In New Trial
- Allergan, Tribe Want PTAB Immunity Denial Reheard En Banc
- Mylan, Pfizer Barely Put Dent In EpiPen Antitrust MDL
- China Biologic's Former CEO Leads $3.9B Takeover Bid
- SEC Ends Bribery Probe Into Chinese Vaccine Co.
- Insys Execs Say Expert Witness Switched Sides
- CVS, Rite Aid Hit AbbVie With Antitrust Suit Over AndroGel
- Stryker's Coverage Claims Over Knee Implants Deemed Viable
- 7th Circ. Gives Law Firm 2nd Shot At Suing Lupin For Fees
- UK Online Fashion Retailer Joins Wave Of IPO Filings
- California Diaper Co. Can't Dodge Massachusetts FCA Suit
- NJ Justices Centralize Zostavax Suits Against Merck
- The 'Post-Fact' Jury In The 'Fake News' Era
- FDA Biosimilars Plan Draws From Experience With Generics
- Latham Fortifies Star IP Trial Team With WilmerHale Atty
- Fixing Rule 41: A Balanced Approach To Voluntary Dismissal
- DOJ's New Policy On FCA Dismissals Highlights Circuit Split
- Client's Benicar Trial Bill Shouldn't 'Scare Off' Firm: Judge
- Promega Gets Damages Appeal All Wrong, Life Tech Says
- Split Fed. Circ. Says Family Can't Get Vaccine Act Relief
- Nationwide Ban OK For Trump Birth Control Rules, States Say
- Lincare Inks $5M FCA Kickbacks Deal Over Waived Copays
- Ex-Lannett Execs Face Derivative Suit Over Antitrust Probes
- Setbacks Shake Up Fla.'s Medical Marijuana Rollout
- Health Hires: Dorsey & Whitney, DLA Piper, Epstein Becker
- Impax Says Opana Deal Didn't Delay Competition
- Ex-Katten Atty Gets 18 Months In Prison For Shkreli Fraud
- Peering Behind The Peer Review Curtain
- Taxation With Representation: Akin Gump, Wachtell, Kirkland
- Judging A Book: Lipez Reviews 'Last Great Colonial Lawyer'
- Will Law Schools Start Counting 'Generation ADA'?
- Ancestry.com Says 23andMe DNA Patent Invalid Under Alice
- TKK Symphony Prices $220M IPO To Pursue China Deal
- 8th Circ. Voids Tax Court Ruling In $1.36B Medtronic Case
- Fed. Circ. Upholds Duties On Compression Garments
- FDA Clears First EpiPen Generic, Made By Teva
- DEA To Cut Drugmaker Production Of Most-Abused Opioids
- Keryx Shouldn't Get 2nd Chance To Ax Stock Suit, Court Told
- 3rd Circ. Won't Revive Allergan Medicaid Rebate Suit
- SEC Nabs 2 Judgments In NY Rep. Insider Trading Case
- Novo Nordisk Can't Dodge Shareholder Suit In NJ
- Monsanto's $289M Roundup Loss Ripples Across Industries
- Athenex Pharma OK'd To Intervene In Par Suit Against FDA
- Buchalter Adds 2 Attys To Corp., Litigation Groups In LA
- NJ High Court Centralizes Some J&J Hernia Mesh Lawsuits
- Rising Star: Winston & Strawn's Kurt Mathas
- A Chat With Ogletree Knowledge Chief Patrick DiDomenico
- 9th Circ. Criticism Of Judicial Notice Trend Is Significant
- Ex-Katten Atty Loses Bid To Dodge Shkreli Fraud Charges
- Out-Of-State Drugs Can Be Taxed, Minn. High Court Rules
- Diagnostics Co. Investors Fight Bid To Nix Stock-Drop Suit
- Masimo, Dominion Settle Suit Over Blood Monitoring Patent
- Blackstone Pours $400M Into Chinese Pharma Co.
- Davis Polk, Cooley Steer ViewRay's $150M Follow-On Offering
- Cabot Inks $1.6B Cash-And-Stock Deal For Chemicals Co.
- Makah Indian Tribe Hits Pharma Cos. With Opioid Crisis Suit
- Rising Star: Sidley Austin's Benjamin M. Mundel
- Ensnarement — A 2nd Bite At The Noninfringement Apple
- How One Firm Moved The Needle On Disability Inclusion
- Deals Rumor Mill: Carlyle, CIE Automotive, Sinochem
- PTAB Shuts Down Hologic Challenges To HIV Detection Patent
- FDA Warning Wire: Concern At Apotex Plant, Poppy Seed Tea
- Speaker Program Payments Weren't Kickbacks, Teva Says
- Fed. Circ. Lets Stand Vanda Ruling That Led To USPTO Memo
- NY Joins Flood Of Opioid Suits Against Purdue Pharma
- DOJ Taps Ex-AG Mukasey To Monitor Bayer-Monsanto Deal
- Time Expired On Defective Zimmer Hip Implant Claim: Judge
- Drug Kickback Suit Against Eli Lilly Dismissed For Now
- PTAB Scraps 2 Aker BioMarine Krill Oil Patents
- Rising Star: Paul Hastings' Isaac Ashkenazi
- Distributors Expose Health, Life Sci Cos. To FCPA Risks
- Interview Essentials For Attorneys On The Move
- 1 NASA Small-Biz Contract, 1 Giant Leap For Plantkind
- Investors Secure Class Cert. In Biotech Stock-Drop Case
- David Boies On How Dyslexia Shaped His Practice
- Relator Dismissed From GE Healthcare False Claims Act Suit
- BigLaw's Mental Health Stigma Shows Signs Of Fading
- States Push Back Against Dismissal Bids In Opioid MDL
- After 'Untenable' IP Case, Judge Says MoFo Is Owed Fees
- ActiveCare Gets Nods On DIP Financing, Auction Plans
- 5 State AGs Argue Against $62B Bayer-Monsanto Deal
- Aralez Gets OK To Tap $5M DIP, Must Produce Budget Info
- Opioid MDL Bellwether Trial Postponed 6 Months
- FTC Overstepped In Shire FDA Petitions Case, 3rd Circ. Told
- 9th Circ. Rips Judicial Notice Trend In Securities Suits
- Fed. Circ. Wrong On HIV Drug Patent Challenge, Justices Hear
- Risk Mitigation Strategies For Gene Therapy Developers
- Warner Media Wants Out Of Benefits Suit Over HIV/AIDS Meds
- Rising Star: Fish & Richardson's Joseph Warden
- Clerking For Ginsburg
- How The Legal Industry Lets Down Lawyers With Disabilities
- Gaining Access: Disabled Lawyers Share Their Stories
- Deals Rumor Mill: Frontier-Suzhou, VF Corp., SIG Combibloc
- J&J Can't Ax Pfizer Antitrust Suit Over Remicade Biosimilar
- Insurer Won't Cover Bias Suit Over Employee's Breast Cancer
- Pending Patent's Inventor Can't Be Disputed, Fed. Circ. Says
- Fla. Medical Provider To Pay $2.2M To End Kickback Claims
- Monsanto Owes $289M In Landmark Roundup Cancer Trial
- Celator Insider Trading Schemers Spared Prison Time
- FDA Focus: What Lowenstein's Practice Chair Is Watching
- Merus Asks High Court To Bat Down Mouse Patent Appeal
- Aralez Sheds Assets For $250M As Bankruptcy Cases Begin
- UK Biotech Co. Closes Latest Funding Round With $84M
- Kavanaugh On Attorney-Client Privilege — 3 Takeaways
- Federal Law Both Sword And Shield In Cannabis Litigation
- Rising Star: Latham & Watkins' Brian Cuneo
- Clerking For Ginsburg: 3 Surprises
- 2nd Circ. Strict On FCA First-To-File Bar In Allergan Case
- Atty Fees In $5M Chinese Award Row Must Also Be Arbitrated
- Mesa Air Group Leads 3 IPOs Raising $260M Combined
- UK Antitrust Watchdog Can Withhold Warrant Info, Court Says
- Lupin Accused Of Hiring Older Sales Pros To Poach Clients
- J&J Hip Implant Plaintiffs Seek $246M Judgment After Trial
- Testing Mandate Is Straining California Cannabis Cos.
- Clerking For Ginsburg: A Superhero Supreme
- Covington Guides Emergent's $270M Vaccine Biz Buy
- Judge Slashes $15M From Pelvic Mesh Verdict Against J&J
- Skadden Leads Chinese Biotech Firm's $903M Hong Kong IPO
- Judge Probes Mental State In Dr. Reddy's Manufacturing Suit
- Lift Block On Trump Birth Control Rules, Gov't Tells 9th Circ.
- Mendocino County Pot Tax Upheld By Calif. Appeals Court
- PTAB Rightly Axed Alcon Eye Drop Patent, Fed. Circ. Says
- J&J Urges Pa. Appeals Court To Undo $2.5M Risperdal Verdict
- TIAA Says It Should Be Only Lead Plaintiff In Valeant Suit
- NJ Woman's Mesh Case Doesn't Belong In Pa., Ethicon Says
- Blockchains: A Better Tool For Supply Chain Management
- Where The Gibson Taxpayers Went Wrong
- Insys To Pay $150M To End DOJ Scrutiny Of Opioid-Rx Bribes
- Why Bristol-Myers Applies To Absent Class Members: Part 3
- Biotech Executive Convicted Of Fraud, Lying To Feds
- Clerking For Ginsburg: 4 RBG Lessons On Having It All
- On-Sale Bar Questions Leading Up To Helsinn At High Court
- China Strikes Back At US Over Latest IP Tariff Escalation
- NY Rep. Chris Collins, Family Charged With Insider Trading
- Monsanto Owes $412M For Roundup 'Reckoning,' Jury Hears
- Fed. Circ. Created Disclosure 'Anarchy,' Amgen Tells Justices
- AstraZeneca Settles Texas Medicaid Fraud Suits For $110M
- AgaMatrix Gets $1.3M Fees From Dexcom's Failed IP Suit
- KKR-Backed Clinical Trials Co. Prices $660M Stock Offering
- Fortuity Rules May Incite Coverage Row Over Opioid Lawsuits
- Tackling Digital Class Notice With Rule 23 Changes
- Scientist Ducks Prison In Medical Device Bribery Scheme
- Why Bristol-Myers Applies To Absent Class Members: Part 2
- Mylan Wants Investors' 'Copycat' EpiPen Claims Dismissed
- Clerking For Ginsburg: How To Play The Long Game
- Monsanto Faces Punitives Bid As Cancer Trial Nears End
- MMA Fighter's Suit Over Dietary Supplements Limps Forward
- Feds, Biotech CEO Spar Over If Lies Were Crimes Or Flubs
- Fla. Bar Seeks Discipline Against South Fla. IP Atty
- Cherokee Nation Wants Purdue Opioid Row In State Court
- ActiveCare Delays Ch. 11 Auction Plan For Committee Talks
- Biopharma Co. Aridis Launches $28M IPO For Clinical Trials
- Providers Say Don't Kill Hospital Bellwether In Opioid MDL
- 3rd Circ. Gives Biomet New Chance To Access Docs In IP Row
- Dental Cos. Look to Straighten Patent Row In Fed. Circ.
- Humana Hits Generic-Drug Makers With Price-Fixing Claims
- Actavis At 5: Where Pay-For-Delay Litigation Stands
- FDA Rejects Opioid Painkiller For The 4th Time
- Why Bristol-Myers Applies To Absent Class Members: Part 1
- Clerking For Ginsburg: In Pursuit Of Precision
- Time To Remove Patent Barriers To US Drug Manufacturing
- High Court Ruling Can't Help Pfizer 'Win The Day' In Class Suit
- CVS Hits Pfizer With Antitrust Suit Over Lipitor Delay
- JPML Bundles Dozens Of Zostavax Suits In Philadelphia
- FTC Can't Block Theoretical Drugmaker Moves, Shire Says
- Ind. Court Tosses Surgery-Privacy Suit Against Stryker
- Ex-Shkreli Atty Claims Companies Can't Be Victims
- PTAB Shoots Down Pfizer's Bid To Review Avastin Patent
- Keryx Wants Auryxia Stock-Drop Suit Reconsidered
- Allergan Sells Dermatology Drugs To Almirall For $650M
- Drugmaker Escapes Stock-Drop Suit Over Opioid Statements
- Juno Investors Reach $24M Deal In Stock-Drop Class Action
- An Upgrade For Expert Evidence Standards In New Jersey
- Genetic Testing Cos. Must Examine Illinois Privacy Law
- Clerking For Ginsburg: My RBG Guide To Judging
- Endo To Pay Texas $13M Over Off-Label Lidoderm Sales
- Bayer, Dow Hit With Polyurethane Price-Fixing Suit
- Otonomy Scores Fed. Circ. Win In Ear Treatment Patent Case
- Allergan Files 3rd-Party Claims Against Pfizer In Opioid MDL
- NJ Accutane Ruling Raises Bar For Expert Witnesses
- Morgan Lewis Adds WilmerHale Partners In Silicon Valley
- It's Prime Time For A Dose Of Reality On Brett Kavanaugh
- Clerking For Ginsburg: 4 Things I Learned
- Merck Can't Sink Cert. In $250M Sex Bias Class Action
- UPDATE: Valeant Says Katten Hires Created Conflict In Drug Patent Suit
- NJ Targets Cos. With Pollution Suits, Some First Since '08
- Opioid MDL Counties Get Partial Info From McKesson Report
- Insider Trader Can't Get Passport Back Ahead Of Sentencing
- Class Attys Want $39M Cut Of $105M Lidoderm Settlement
- NJ Justices Say Unreliable Evidence Kills Accutane MDL
- Top Product Liability Cases Of 2018: Midyear Report
- Valeant Can't Escape RICO Claims In 3 Investor Fraud Suits
- White House Sets Out 2020 R&D Focus For US Agencies
- Benecol Buyers Seek Class Cert. In Trans Fat False Ad Suit
- Grifols To Divest 3 US Plasma Centers As Part Of $286M Deal
- NewLink Looks To Nix Investor Suit Over Cancer Drug, Again
- Strategies For Dealing With US-China Tariffs
- Clerking For Ginsburg: The Equality Lessons